Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dinalbuphine Sebacate Extended Release Injection for Postoperative Pain
ChiCTR2100045554Phase 3Recruiting
- Sponsor
- Renji Hospital
- Start
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in postoperative pain comparing dinalbuphine sebacate with Control: placebo (2 arms). Primary endpoint: Total amount of morphine used within 48 hours after surgery. Started Sep 2020; status: recruiting.
02
Drugs
dinalbuphine sebacate
03
Conditions
postoperative pain
Beyond the preview
Go deeper on ChiCTR2100045554.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100045554.